New cytostatic agents for the treatment of head and neck cancer

Acta Oto-Rhino-Laryngologica Belgica

Volumn 51, Issue 2, 1997, Pages 61-68

  Devriendt, D ^a   Klastersky, J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

cytostatic agents; head and neck cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRITREXIM; VINCRISTINE;

CHEMOTHERAPY; DRUG DEVELOPMENT; DRUG EFFICACY; HEAD AND NECK CANCER; LEUKOPENIA; NEUTROPENIA; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; TAXOIDS;

EID: 0030922687     PISSN: 00016497     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. TAVORATH R., PFISTER D. G. Chemotherapy for recurrent disease and combined modality therapy for head and neck cancer. Opin. Oncol., 1995, 7: 242-7.
2. STUPP R., WEICHSELBAUM R. R., VOKES E. E. Combined modality therapy of head and neck cancer. Semin. in Oncol., 1994, 21 : 349-58.
3. JACOBS C., PINTO H. Adjuvant and neoadjuvant treatment of head and neck cancers : the next chapter. Semin. Oncol., 1995, 22 : 540-52.
4. VOKES E. E., WEICHSELBAUM R. R. Concomitant chemotherapy : rationale and clinical experience in patients with solid tumors. J. Clin. Oncol., 1990, 8: 911-34.
5. HARARI P. M., KINSELLA T. J. Advances in radiation therapy for head and neck cancer. Curr. Opin. Oncol., 1995, 7 : 248-54.
6. ARMAND J. P., BOUTEAU C. Chemotherapy in head and neck cancer. Eur. J. Cancer, 1995, 31-A : 819-22.
7. URBA S. G., FORASTIERE A. A. Systemic therapy of head and neck cancer. Oncology, 1989, 3 : 79-88.
8. MURPHY B. A. New drug therapy for squamous carcinoma of the head and neck. Current Opin. Oncol., 1996, 8 : 221-26.
9. VOKES E. E., HARAF D. J., STENSON K. et al. The role of paclitaxel in the treatment of head and neck cancer. Semin. Oncol., 1995, 22 (n° 5, suppl. 12) : 8-12.
10. FORASTIÈRE A. A. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin. Oncol., 1994, 21 (n° 5, suppl. 8) : 49-52.
11. STEINBERG L., HASSAN M., HOPPEL et al A phase I study or radiotherapy and simultaneous paclitaxel in patients with locally advanced squamous cell carcinoma of the head and neck. Proceedings of ASCO, 1996, 15 : 913.
12. BUESA J. M., FERNANDEZ R., ESTEBAN et al. Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann. Oncol., 1991, 2 : 1512.
13. PAI V. R., PARIKH M., MAZUMBAR A. T., RAO R. S. Phase II study of high-dose ifosfamide as a single agent in combination with cisplatin in the treatment of advanced and/or recurrent squamous cel carcinoma of head and neck. Oncology, 1993, 50 : 86-96.
14. FORASTIÈRE A. A., URBA S. G., LIGGETT D. F., MILLER D. F. Paclitaxel and ifosfamide combination chemotherapy in advanced head and neck cancer : toxicity is sequence dependent. Proceedings of ASCO, 1995, 14 : 845.
15. BENNER S. E., LIPPMAN S. M., HUBER M. H., HONG W. K. Phase I study of paclitaxel, cisplatin and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. Semin. Oncol., 1995, 22 (n° 5, suppl. 12) : 22-5.
16. HANAUSKE A. R., SCHILLING T., HEINRICH B. et al. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Semin. Oncol., 1995, 22 (n° 6, suppl. 14) : 35-9.
17. HITT R., HORNEDO J., COLOMER R. et al. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers : preliminary results. Semin. Oncol., 1995, 22 (n° 6, suppl. 15) : 50-4.
18. KHAMBU S., CLAMON G., DOORNBOS R. et al. Phase II trial of taxol and cisplatin in advanced squamous cell carcinoma of the head and neck. Proceedings of ASCO, 1996, 15 : 917.
19. CREAVEN P., RAGHAVAN D., PENDYALA L. et al. Phase I study of paclitaxel and carboplatin : implications for trials in head and neck cancer. Semin. Oncol., 1995, 22 (n° 5, suppl 12) : 13-6.
20. DUNPHY F., BOYD J., VARVARES M. et al Phase I trial of preoperative chemotherapy using paclitaxel/ paraplatin in head and neck carcinoma. Proceedings of ASCO, 1996, 15 : 862.
21. AISNER J., BELANI C. P., KEARNS C. et al. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Semin. Oncol., 1995, 22 (n° 5, suppl. 12) : 17-21.
22. CHOUGULE P., WEHBE T., LEONE L. et al. Concurrent taxol carboplatin and radiotherapy in advanced head and neck cancers : a phase II study. Proceedings of ASCO, 1996, 15 : 898.
23. POSNER M., DREYFUSS A., CLARK J. et al. Docetaxel for advanced, incurable squamous cell carcinoma of the head and neck (SCCHN). Proceedings of ASCO, 1996, 15 : 889.
24. COUTEAU C., LEYVRAZ S., OULID-AISSA D. et al. A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck. Proceedings of ASCO, 1996, 15 : 889.
25. CATIMEL G., VERWEIJ J., MATTIJSSEN V. et al. Docetaxel (Taxotere) : an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol., 1994, 5 : 533-7.
26. SCHÖFFSKI P., WANDERS J., CATIMEL G. et al. Docetaxel and cisplatin : a highly active regimen for squamous cell carcinoma of the head and neck. Proceedings of ASCO, 15 : 871.
27. GEBBIA V., TESTA A., VALENZA R. et al. A pilo study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur. J. Cancer, 1993, 29-A : 1358-9.
28. GEBBIA V., TESTA A., VALENZA R. et al. Vinorelbine plus cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell head and neck carcinoma. Proceedings of ASCO, 1993, 12 : 917.
29. LUND B., KRISTJANSEN P. E. G., HANSEN H. H. Clinical and preclinical activity of 2′, 2′-difluoro-deoxycytidine (gemcitabine). Cancer Treat Rev., 1993, 19 : 45-9.
30. CATIMEL G., VERMORKEN M., CLAVEL P. et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol., 1994, 5 : 543-7.
31. ROBERT F., WHEELER R. H., MOLTHROP D. C., GREENE P., CHEN S. Phase II study of topotecan in advanced Head and neck cancer : identification of an active new agent. Proceedings of ASCO, 1994, 13 : 905.
32. SCHORNAGEL J. H., VERWEIJ J., DE MULDER P. H. M. et al. A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. Ann. Oncol., 1992, 3 : 223-6.
33. SCHORNAGEL J. H., VERWEIJ J., DE MULDER P. H. M. et al. Randomized phase III/II trial of edatrexate versus methotrexate in patients with metastatic and/ or recurrent squamous cell carcinoma of the head and neck : a European Organisation for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group Study. J. Clin. Oncol., 1995, 13 : 1649-55.
34. DEGARDIN M., DOMENGE C., CAPPELAERE P. et al. Phase II study of piritrexim in patients with advanced squamous cell carcinoma of the head and neck. Eur. J. Cancer. 1994, 30-A : 1044-5.
35. KLASTERSKY J. New drug of therapy of non-small cell lung cancer. Lung Cancer, 1994, 11 (suppl. 3) : S139-S149.
36. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report. Cancer, 1987, 60 : 301-311.
37. SCHULLER D. E., METCH B., MATTOX D. et al. Prospective chemotherapy in advanced resectable head and neck cancer : Final report of the South-west Oncology Group. Laryngoscope, 1988, 98 : 1205-1211.
38. LARAMORE G. E., SCOTT C. B., AL-SARRAF M. et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck : Report on Intergroup Study. Int. J. Radiat. Oncol. Biol. Phys., 1992, 23: 705-713.
39. WOLF G., HONG W., FISHER S. et al. Larynx preservation with induction chemotherapy and radiation in advanced laryogeal cancer : Final results of the VA Laryngeal Cancer Study Group cooperative trial. Proc. Am. Soc. Clin. Oncol., 1993, 12 : 277 (abstr. 892).